Evidence map›Paper›PMID 35785036›Full record

ArticleJournal of immunology research2022

Peptidoglycan-Like Components in Z-100, Extracted from

Takayuki Horii, Yuki Orikawa, Yuta Ohira, Runa Eta, Uiko Tominaga, Takanori Sato, Takao Tanaka

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takayuki HoriiCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0001-7349-2147
Yuki OrikawaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0002-0806-6237
Yuta OhiraCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0001-7800-3736
Runa EtaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0003-0211-4506
Uiko TominagaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0001-5746-6635
Takanori SatoCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0002-7935-1182
Takao TanakaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya City, 360-0111 Saitama, Japan.ORCID https://orcid.org/0000-0001-9311-256X
Zeria Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Z-100 is a hot-water extract of the human-type Methods: Mouse bone marrow-derived cells and CD14 Results: While Z-100 stimulation increased the production of interleukin- (IL-) 12p40 and IL-1 Conclusion: Z-100 induced the production of immunomodulatory cytokines from various types of macrophages and specifically increased IL-12p40 production through peptidoglycan-like components via NOD2.

Indexed as

Mycobacterium tuberculosisAnimalsInterleukin-12 Subunit p40LipidsMannansMiceNod2 Signaling Adaptor ProteinPeptidoglycanTumor Necrosis Factor-alphaInterleukin-12 Subunit p40LipidsMannansNod2 protein, mouseNod2 Signaling Adaptor ProteinPeptidoglycanspecific substance maruyamaTumor Necrosis Factor-alpha

Identifiers

PMID35785036
PMCPMC9242757
OpenAlexW4283330740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.